Laekna Pharmaceutical Ningbo Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors found to be potentially useful for the treatment of cancer.

Researchers from Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase (such as Von Hippel-Lindau disease tumor suppressor [VHL]) coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.

Shanghai Yingli Pharmaceutical Co. Ltd. has discovered hydrazine-structured compounds as inhibitors of GTPase KRAS and its mutants. They are reported to be useful for the treatment of cancer.

Page Therapeutics AG has synthesized bufalin derivatives reported to be useful for the treatment of metastatic cancer.

Pharmgen Science Inc. has patented H+/K+-ATPase inhibitors that are potentially useful for the treatment of asthma, esophagitis, Helicobacter pylori infection, gastroesophageal reflux disease, gastritis, peptic ulcer and more.

CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have patented new serine protease NS3/nonstructural protein 2B (NS3/NS2B) (flavivirus) inhibitors potentially useful for the treatment of West Nile and Zika virus infections.

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have identified new calcitonin receptor (CALCR; CT-R) and amylin receptor dual agonists potentially useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; NASH), overweight, dyslipidemia, cognitive and cardiovascular disorders.

The University of Melbourne has reported new radionuclide-drug conjugates (RDCs) comprising copper ion chelated to sarcophagine covalently bound to a peptide-targeting glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) and another peptide targeting gastrin-releasing peptide receptor (GRPR).

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3 receptor agonists potentially useful for the treatment of neurological and psychiatric disorders.

The University of North Carolina at Chapel Hill has disclosed new large neutral amino acids transporter small subunit 1 (SLC7A5; LAT1) inhibitors reported to be useful for the diagnosis and treatment of cancer.